Characteristic | 5-gene panel (n = 136) | mam(n = 29) | PSE(n = 58) |
---|---|---|---|
Histologic Grade | Â | Â | Â |
   I | 31/63 (49.2%) | 3/63 (4.8%) | 15/63 (23.8%) |
   II-III | 98/143 (68.5%) | 22/143 (15.4%) | 42/143 (29.4%) |
 | P = 0.0083 | P = 0.0315 | P = 0.4110 |
Nodal Metastases (Path) | Â | Â | Â |
   N0 | 97/150 (64.7%) | 18/150 (12.0%) | 46/150 (30.7%) |
   N1 | 37/64 (57.8%) | 10/64 (15.6%) | 12/64 (18.8%) |
 | P = 0.3427 | 0.4715 | P = 0.0726 |
ER Status | Â | Â | Â |
   ER-neg | 28/46 (60.9%) | 10/46 (21.7%) | 6/46 (13.0%) |
   ER-pos | 98/154 (63.6%) | 17/154 (11.0%) | 49/154 (31.8%) |
 | P = 0.7331 | P = 0.0624 | P = 0.0123 |
PR Status | Â | Â | Â |
   PR-neg | 40/67 (59.7%) | 11/67 (16.4%) | 12/67 (17.9%) |
   PR-pos | 79/120 (65.8%) | 16/120 (13.3%) | 42/120 (35.0%) |
 | P = 0.4033 | P = 0.5650 | P = 0.0134 |
Risk Category | Â | Â | Â |
   Low/Intermediate Risk | 20/34 (58.8%) | 2/34 (5.9%) | 9/34 (26.5%) |
   High Risk | 116/181 (64.1%) | 27/181 (14.9%) | 49/181 (27.1%) |
 | P = 0.5861 | P = 0.2698* | P = 0.9564 |